NEW YORK (360Dx) – Roche on Friday said that its PD-L1 assay has received CE-label expansion to identify untreated and previously treated patients with metastatic non-small cell lung cancer that are eligible for Merck's Keytruda (pembrolizumab) immunotherapy.

As a result, the Ventana PD-L1 (SP263) Assay — the only fully automated PD-L1 test for use with Keytruda to launch on Roche's BenchMark series of instruments — is available in countries accepting the CE mark, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.